Out of the 25 soluble factors measured, four were significantly different (p < 0.05) between HD and CHC patients who were going to initiate IFN-free DAA therapy: CCL5, CXCL10, sCD14 and sCD163 (Fig. 1a). This evidence concerns the gene CCL5 and cryohydrocytosis.